Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Johnson & JohnsonJNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

This week's dividend activity included increased payouts from Citigroup (NYSE:C) and Duke Energy (DUK) as well as ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

The healthcare industry offers many attractive dividend investments. Both Johnson & Johnson as well as Pfizer have a positive outlook.

The CDC has approved eligibility guidelines for the Pfizer vaccine booster. Recommendations for Moderna and Johnson & Johnson could come soon.

Comparing the COVID-19 vaccines: If you have a choice, which one should you get? Pfizer, Moderna and Johnson & Johnson are all safe and effective, but there are some differences.

Health experts say not to hold out for a certain vaccine. But Pfizer, Moderna and Johnson & Johnson doses are available in Illinois. Can you choose?

Johnson & Johnson's vaccine won't capture nearly as much market share as Pfizer and Moderna this year. The company's vaccine has been at a disadvantage due to a perceived lower efficacy rate. Its ...